PDS Biotechnology Corp expected to post a loss of 25 cents a share - Earnings Preview

PDS Biotechnology

12/05/2025 14:37

PDS Biotechnology Corp PDSB.OQ PDSB.O is expected to show no change in quarterly revenue when it reports  results on May 14 for the period ending March 31 2025

​LSEG's mean analyst estimate for PDS Biotechnology Corp is for a loss of 25 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 5.4% in the last three months. ​

Wall Street's median 12-month price target for PDS Biotechnology Corp is $6.50​, above​ its last closing price of $1.20. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.28
-0.21
Beat
24.1
Sep. 30 2024
-0.27
-0.28
-0.29
Missed
-4.2
Jun. 30 2024
-0.33
-0.34
-0.23
Beat
32​
Mar. 31 2024
-0.37
-0.37
-0.30
Beat
18.2
​​Dec. 31 2023
-0.60
-0.44
-0.35
Beat
20.2
Sep. 30 2023
-0.44
-0.45
-0.35
Beat
21.5​
Jun. 30 2023
-0.35
-0.35
-0.37
Missed
-6.6
Mar. 31 2023
-0.31
-0.31
-0.32
Missed
-4.7

This summary was machine generated May 12 at 13:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)